Our Pricing

Buy Wegovy FlexTouch Pen Online UK with Fast Prescription

Published on: June 03, 2026

When you buy Wegovy FlexTouch pen online UK through Cured Pharmacy, you access genuine UK-licensed semaglutide injections from £79.00, complete with a free clinical consultation by our UK-registered prescribers. Our streamlined service delivers prescription weight loss treatment directly to your door with complete discretion and regulatory compliance.

How Wegovy FlexTouch Pen Works for Weight Loss

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for chronic weight management in adults with a body mass index of 30 kg/m² or greater, or 27 kg/m² with weight-related comorbidities [1]. Semaglutide mimics a natural hormone that regulates appetite and food intake by acting on areas of the brain that control hunger.

The FlexTouch pen delivery system provides pre-filled, single-dose injections administered once weekly via subcutaneous injection. Clinical trials demonstrate that semaglutide 2.4 mg produces significant weight reduction by slowing gastric emptying, reducing appetite, and improving glycaemic control [1][2].

In the landmark STEP 1 trial, participants receiving semaglutide 2.4 mg achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [2]. These results represent one of the most substantial weight loss outcomes observed in pharmaceutical trials for obesity management.

Wegovy Dosing Schedule and FlexTouch Pen Strengths

The gradual escalation protocol significantly reduces the incidence of nausea and vomiting, which are the most commonly reported side effects during initial treatment [3]. Most patients tolerate dose increases well when following the recommended four-week intervals between adjustments.

If you experience persistent gastrointestinal symptoms, your prescriber may delay dose escalation by an additional four weeks. Clinical guidance from NICE emphasises individualised dosing based on tolerance and response, rather than rigid adherence to timelines when side effects are problematic [4].

Gradual Dose Escalation Protocol

Wegovy treatment follows a structured dose escalation schedule designed to minimise gastrointestinal side effects whilst optimising therapeutic outcomes. Your UK prescriber will typically start you on 0.25 mg weekly for four weeks, then increase to 0.5 mg, 1.0 mg, 1.7 mg, and finally the maintenance dose of 2.4 mg weekly [3].

Each FlexTouch pen contains a single dose and is disposed of after use. The pen features a simple injection mechanism requiring no manual needle attachment, making self-administration straightforward for most patients. Injection sites typically rotate between the abdomen, thigh, or upper arm to reduce localised reactions.

Buy Wegovy FlexTouch Pen Online UK: Our Prescription Process

Transparency defines our service. The price you see before consultation—from £79.00 for Wegovy—is the final price you pay, with no hidden fees or surprise charges at checkout. This upfront pricing model ensures you make informed decisions about your weight loss treatment investment.

All Wegovy FlexTouch pens supplied by Cured Pharmacy are genuine UK-licensed medicines sourced through legitimate pharmaceutical supply chains. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), personally oversees quality assurance and regulatory compliance across every prescription fulfilled.

3-Minute Online Consultation

Our clinical assessment takes under three minutes to complete and covers your medical history, current medications, weight loss goals, and any contraindications to GLP-1 therapy. You'll answer questions about cardiovascular health, thyroid conditions, pancreatitis history, and diabetic status to ensure Wegovy is clinically appropriate.

A UK-registered prescriber reviews every consultation individually—we never use automated approvals. If Wegovy is suitable, your prescription is issued electronically to our GPhC-registered pharmacy, and your medication is dispensed the same working day for next-day delivery across the UK.

Wegovy vs Other GLP-1 Weight Loss Treatments

Several GLP-1 receptor agonists are now licensed for weight management in the UK, each with distinct pharmacological profiles and clinical evidence bases. Semaglutide (Wegovy) and liraglutide (Saxenda) both target the GLP-1 pathway, whilst tirzepatide (Mounjaro) activates both GLP-1 and GIP receptors for dual incretin activity.

Wegovy offers once-weekly dosing compared to daily injections required for liraglutide, which many patients find more convenient for long-term adherence. Clinical head-to-head data show semaglutide produces greater average weight reduction than liraglutide, with the STEP 8 trial demonstrating 15.8% weight loss with semaglutide versus 6.4% with liraglutide over 68 weeks [5].

Newer dual-agonist therapies show promise for even greater efficacy in clinical trials, though individual response varies considerably. Your prescriber will recommend the most appropriate GLP-1 therapy based on your medical profile, treatment goals, dosing preferences, and tolerance to gastrointestinal effects.

Common Side Effects and Safety Considerations

Serious but rare adverse events include pancreatitis, gallbladder disease, and thyroid C-cell tumours observed in rodent studies (though not confirmed in humans) [3]. Wegovy is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

If you develop severe abdominal pain, persistent vomiting, or signs of pancreatitis, discontinue Wegovy immediately and seek medical attention. Your prescriber will conduct a thorough safety assessment during consultation to identify any contraindications before prescribing.

Managing Gastrointestinal Symptoms

Nausea is the most frequently reported side effect with Wegovy, affecting approximately 44% of patients in clinical trials, though typically diminishing over the first few weeks of treatment [2]. Other common gastrointestinal effects include diarrhoea, constipation, vomiting, and abdominal discomfort.

Practical strategies to minimise nausea include eating smaller, more frequent meals, avoiding high-fat foods, staying well-hydrated, and injecting at bedtime so peak nausea occurs during sleep. Most gastrointestinal side effects resolve within 4-8 weeks as your body adjusts to the medication.

Long-Term Weight Maintenance with Wegovy

NICE guidance recommends continuing Wegovy only if patients achieve at least 5% weight loss after 6 months of treatment at the maintenance dose [4]. Regular monitoring by healthcare professionals helps assess response, manage side effects, and adjust treatment plans based on individual progress and tolerance.

At Cured Pharmacy, we support long-term treatment with straightforward repeat prescription services. Once established on Wegovy, you can reorder through a simplified consultation process, ensuring continuity of care without repeated lengthy assessments. Our clinical team remains available for questions throughout your weight loss journey.

Combining Medication with Lifestyle Changes

Wegovy is licensed as an adjunct to a reduced-calorie diet and increased physical activity, not as monotherapy [4]. Clinical trials enrolled participants who received intensive behavioural counselling alongside medication, and real-world outcomes depend significantly on concurrent lifestyle modifications.

Evidence from the STEP 4 trial demonstrates that discontinuing semaglutide after 20 weeks resulted in participants regaining two-thirds of their lost weight over the subsequent 48 weeks [6]. This underscores that Wegovy treats a chronic condition requiring ongoing pharmacotherapy for sustained weight management.

Scientific References

1. Davies, M., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity. Technology appraisal guidance [TA875]. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
5. Rubino, D. M., et al. (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA, 327(2), 138–150. https://doi.org/10.1001/jama.2021.23619 [accessed 13 August 2026]
6. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with a body mass index of 30 kg/m² or greater, or 27 kg/m² with at least one weight-related comorbidity.